What is the history of Pulmonary Hypertension?

Pulmonary Hypertension was first identified in the late 19th century, with the first clinical description attributed to Ernst von Romberg in 1891. Over the last century, our understanding of Pulmonary Hypertension has shifted from a poorly understood "primary" condition to a complex, multifaceted disease categorized into five distinct clinical groups based on underlying causes and treatment pathways.

Who first described Pulmonary Hypertension?

The history of Pulmonary Hypertension began in 1891 when the German physician Ernst von Romberg described "pulmonary vascular sclerosis" in a patient during an autopsy. For decades following this discovery, the condition was shrouded in mystery, often labeled as "primary" or "idiopathic" because doctors could not identify an external cause for the elevated blood pressure in the lung arteries. It wasn't until the mid-20th century, with the development of cardiac catheterization, that physicians could finally measure pulmonary artery pressures in living patients, turning Pulmonary Hypertension from a post-mortem curiosity into a clinical diagnosis.

How has our understanding of the disease evolved?

The classification of Pulmonary Hypertension underwent a major paradigm shift at the World Symposiums on Pulmonary Hypertension, which began in 1973. Experts moved away from the binary "primary vs. secondary" model to a more nuanced five-group system. This evolution helped researchers recognize that Pulmonary Hypertension is not a single disease but a final common pathway for many different conditions, ranging from left-sided heart disease and chronic lung disease to autoimmune disorders and blood clots.

What are the major milestones in treatment?

The history of treating Pulmonary Hypertension is a story of moving from supportive, palliative care to targeted, life-extending therapies. Significant milestones include:

• 1980s: The introduction of continuous intravenous epoprostenol, which revolutionized the management of severe disease.


• 1990s: The discovery of the endothelin pathway led to the development of oral medications, making treatment less invasive.


• 2000s: The approval of phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase stimulators provided more options for vasodilation.


• Modern Era: Current research focuses on combination therapies that target multiple biological pathways simultaneously to improve patient outcomes.

How have technology and genetics changed the landscape?

The identification of the BMPR2 gene mutation in 2000 transformed the study of hereditary Pulmonary Hypertension. This discovery allowed genetic counselors to offer testing to families, providing clarity for those with a history of the disease. Furthermore, the 101 members of the DiseaseMaps community currently navigating this condition benefit from modern imaging technology, such as high-resolution echocardiography and right heart catheterization, which allow for earlier detection and more precise hemodynamic monitoring than ever before.

Next steps

• Consult a board-certified pulmonologist or cardiologist who specializes in Pulmonary Hypertension.


• Join the DiseaseMaps.org community to connect with the 101 members currently sharing their lived experiences.


• Ask your medical team about the latest clinical trials and registries for your specific classification of the disease.


• Request a referral to a specialized center of excellence for a comprehensive multidisciplinary evaluation.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• Pulmonary Hypertension Association (PHA)


• PubMed: World Symposium on Pulmonary Hypertension Clinical Classifications